Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-25 of 141 for your search:
Start Over
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TG4010.14/TIME, NCI-2013-00825, 8559, TG4010.14/TIME, 8559, NCT01383148
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 103A-301, NCI-2012-01351, NCT01546571
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NLG0505, NCI-2013-01044, 1210-1195, NCT01836432
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Phase III Trial of Maintenance FANG™ for High Risk Stage III/IV Ovarian Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-PTL-119, NCI-2015-01040, NCT02346747
Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC038C, NCI-2009-01194, Mod06-005263-65, MAYO-MC038C, MAYO-06-005263, NCT00450814
Vaccine Therapy, Rituximab, Peripheral Blood Stem Cell Transplant, and Therapeutic Autologous Lymphocytes in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: LYMNHL0040-BMT212, NCI-2011-00136, 5089, 96940, NCT00490529
Vaccine Therapy in Treating Patients With Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 04-101, NCI-2011-02468, NCT00669136
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
Vaccine Therapy in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC29810, NCI-2011-00285, NCT01312389
Laboratory-Treated Therapeutic Autologous Lymphocytes in Treating Patients With Advanced Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: UPCC 01411, NCI-2011-00960, NCT01352286
Vaccine Therapy in Treating Patients with Stage IV Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16439, NCI-2012-00431, MCC-16439, NCT01433172
Vaccine Therapy and Lenalidomide in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: H-30087, NCI-2013-01015, RV-CLL-PI-0715, TAIL, NCT01604031
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BrUOG 276, NCI-2014-00505, NCT01671488
Vaccine Therapy in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 11-094, NCI-2013-00081, NCT01720836
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: BP-HM-001, NCI-2013-00518, NCT01744223
Viral oncoprotein targeted autologous T cell therapy for Merkel cell carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2586.00, NCI-2012-02779, 2586, NCT01758458
Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7866, NCI-2013-01377, 135, 7866/135, NCT01922921
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HS410-101, NCI-2014-01420, NCT02010203
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: HPV-004, NCI-2015-00497, NCT02172911
Start Over